William L. Macias - 11 Jun 2021 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Role: Chief Medical Officer
Signature: /s/ Pamela Yanchik Connealy, attorney-in-fact for William L. Macias
Issuer symbol: IMVT
Transactions as of: 11 Jun 2021
Net transactions value: $0
Form type: 4
Filing time: 15 Jun 2021, 08:56:36 UTC
Previous filing: 10 Jun 2021
Next filing: 16 Sep 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IMVT	Common Stock	Award	$0	+18,674		$0.000000	18,674	11 Jun 2021	Direct	F1, F2
transaction	IMVT	Common Stock	Award	$0	+93,371	+500%	$0.000000	112,045	11 Jun 2021	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IMVT	Stock Option (right to buy)	Award	$0	+369,320		$0.000000	369,320	11 Jun 2021	Common Stock	369,320	$10.71	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares underlying restricted stock units awards ("RSUs").
F2	The RSUs vest over four years, with 25% of the RSUs vesting on April 13, 2022 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.
F3	The RSUs vest in their entirety on December 31, 2021, subject to the Reporting Person providing continuous service to the Issuer as of such date.
F4	Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on April 13, 2022 and the remainder of the shares underlying the options vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.